Identifying driver mutations in cancer is notoriously difficult. To date, recurrence of a mutation in patients remains one of the most reliable markers of mutation driver status. However, some mutations are more likely to occur than others due to differences in background mutation rates arising from various forms of infidelity of DNA replication and repair machinery, endogenous, and exogenous mutagens.
Introduction
Cancer is driven by changes at the nucleotide, gene, chromatin, and cellular levels. Somatic cells may rapidly acquire mutations, one or two orders of magnitude faster than germline cells [1] .
The majority of these mutations are largely neutral (passenger mutations) in comparison to a few driver mutations that give cells the selective advantage leading to their proliferation [2] . Such a binary driver-passenger model can be adjusted by taking into account additive pleiotropic effect of mutations [3, 4] . Mutations might have different functional consequences in various cancer types and patients, they can lead to activation or deactivation of proteins and dysregulation of a variety of cellular processes. This gives rise to high mutational, biochemical, and histological intraand inter-tumor heterogeneity that explains the resistance of cancer to therapies and complicates the identification of driving events in cancer [5, 6] .
Point DNA mutations can arise from various forms of infidelity of DNA replication and repair machinery, endogenous, and exogenous mutagens [6] [7] [8] [9] . There is an interplay between processes leading to DNA damage and those maintaining genome integrity. The resulting mutation rate can vary throughout the genome by more than two orders of magnitude [10, 11] due to many factors operating on local and large scales [12] [13] [14] . Many studies support point mutation rate dependence on the local DNA sequence context for various types of germline and somatic mutations [9, 11, 13, 15] whereas local DNA sequence context has been identified as a dominant factor explaining the largest proportion of mutation rate variation in germline and soma [10, 16] . Additionally, differences in mutational burden between cancer types suggest tissue type and mutagen exposure as important confounding factors contributing to tumor heterogeneity.
Assessing background mutation rate is crucial in identifying significantly mutated genes [17, 18] , sub-gene regions [19, 20] , mutational hotspots [21, 22] , or prioritizing mutations [23] . This is especially important considering that the functional impact of the majority of changes observed in cancer is poorly understood, in particular for rarely mutated genes [24] . Despite this need, there is a persistent lack of quantitative information on per-nucleotide background rates of cancer somatic mutations in different gene sites in various cancer types and tissues. In this study we developed probabilistic models that estimate background mutability per nucleotide or codon substitution. Mutability is defined as a probability to obtain a nucleotide or codon substitution purely from the underlying background processes of mutagenesis and repair; those processes act on genome-wide scale and are devoid of cancer selection component affecting a specific genomic (or protein) site. The models (mutational profiles) were constructed under the assumption that vast majority of cancer context-dependent mutations have neutral effects, while only a negligible number of these mutations in specific sites are under selection. To assure this, we removed all recurrent mutations as these mutations might be under selection in cancer. Mutational profiles were calculated by sampling the frequency data on types of mutations and their trinucleotide (for nucleotide mutations) and pentanucleotide (for codon substitutions) contexts regardless of their genomic locations. These models in the forms of mutational profiles can be used to estimate the expected mutation rate in a given exonic site as a result of different local or long-range context-dependent mutational processes.
There are many computational methods that aim to detect driver genes and fewer methods trying to rank mutations with respect to their potential carcinogenicity. As many new approaches to address this issue have been developed [25] [26], it still remains an extremely difficult task and many driver mutations, especially in oncogenes, are not annotated as high impact or disease related [27] even though cancer mutations harbor the largest proportion of harmful variants [28] . We apply our model to decipher the contribution of background DNA mutability in the observed mutational spectrum in cancer for missense, nonsense, and silent mutations. We compiled a set of cancer driver and neutral missense mutations with experimentally validated impacts collected from multiple studies and used this set to verify our method and compare it with other existing methods. Our approach has been implemented online as part of the MutaGene web-server: https://www.ncbi.nlm.nih.gov/research/mutagene/gene.
Results

Mutations not observed in cancer patients have low mutability
We analyzed all 3,293,538 theoretically possible codon substitutions that could have occurred by single point mutations in 520 cancer census genes and found that only about one percent of them were actually observed in the surveyed 12,013 tumor samples derived from the COSMIC v85 dataset (Table S1 ). For codon substitutions which were not observed, the average mutability (µ = 1.29 x 10 -6 ) was found to be three-fold lower compared to the mutability (see Methods) of codon substitutions observed in patients for all types of mutations (µ = 3.88 x 10 -6 ), Mann-Whitney-Wilcoxon test, < 0.01. This finding holds true for per-nucleotide mutability (µ = 1.04
x 10 -6 versus µ = 3.36 x 10 -6 , Mann-Whitney-Wilcoxon test, < 0.01) ( Figure 1 ). As a validation of this finding, we also explored mutability and mutation frequency in a set of 9,228 patients who had undergone prospective sequencing of MSK-IMPACT gene panel ( Figure S1 ). Looking at mutations in the genes which were sequenced in all patients in the MSK-IMPACT cohort, the same pattern remains that observed codons mutations had a higher mutability (µ = 3.41 x 10 -6 ), compared to those which were theoretically possible, but did not occur (µ = 1.29 x 10 -6 ,Mann-Whitney-Wilcoxon test, < 0.01). Importantly, none of this subset of tumor samples were involved in deriving mutability values, thus showcasing the applicability mutability derived from one cohort to another.
Figure S2 shows cumulative and probability density distributions of nucleotide mutability values
for all observed in patients and possible mutations in all cancer census genes and for two genes in particular, CASP8 and TP53, as examples. While there are many more possible mutations with low mutability values, the observed cancer spectrum is dominated by mutations with high mutability. A similar pattern is seen using cancer-specific mutability values ( Figure S3 ). Mutations which are not observed in breast, lung carcinoma, colon adenocarcinoma, and skin melanoma cancer samples have substantially lower mutability, and as mutability increases, mutations reoccur in more patients, and this is true for both COSMIC v85 and MSK-Impact cohorts. Figures 2A,B show the distributions of codon mutability values for all possible missense, nonsense, and silent mutations accessible by single nucleotide base substitutions in the proteincoding sequences of 520 cancer census genes calculated with the pan-cancer background model.
Silent mutations have highest mutability
Codon mutability spans two orders of magnitude and silent mutations have significantly higher average mutability values (µ = 5.68 x 10 -6 ) than nonsense (µ = 3.44 x 10 -6 ), or missense mutations (µ = 3.29 x 10 -6 ) according to Kruskal-Wallis test ( < 0.01) and Dunn's post hoc test ( < 0.01) for all comparisons. These differences in codon mutabilities could be a reflection of the degeneracy of genetic code, where multiple silent nucleotide substitutions in the same codon may increase its mutability (as illustrated in Figure S4 ). However, while the differences between types of mutations are less pronounced for nucleotide mutability ( Figure 2C ), silent mutations are still characterized by the highest mutability values.
Background mutability may shape the observed mutational spectrum in cancer
Under the null model of all mutations arising as a result of background mutational processes, somatic mutations should accumulate with respect to their mutation rate and one would expect a positive correlation between mutability and observed mutational frequency of individual mutations. Indeed, as Figures 2B,D show, this is clearly the case for silent and nonsense mutations. To further investigate this relationship, we calculated Spearman's rank (a nonparametric test taking into account that mutability is not normally distributed) and Pearson linear correlation coefficients between codon mutability and frequencies of mutations observed in 12,301 whole-exome (WES) and whole-genome (WGS) tumor samples in the COSMIC cohort ( Figure 3 ). Pooling together all types of mutations in cancer census genes resulted in a very low but significant positive correlation between codon mutability and mutation frequency ( = 0.13 and = 0.02 for Spearman and Pearson, respectively, < 0.01), as shown in Figure S5A .
Breaking up all codon changes into silent, nonsense and missense reveals higher correlations, particularly for silent ( = 0.14, = 0.1, < 0.01) and nonsense ( = 0.20, = 0.15, < 0.01) mutations ( Figure S5A ). We also calculated correlation coefficients for each gene with at least ten unique mutations of each type: silent, nonsense, and missense ( Figure 3 ). Overall, we found 84 and 137 genes with significant ( < 0.01) positive Spearman and Pearson correlations, respectively, for at least one mutation type (Table S2 ). Among the genes with significant correlations, 41 belonged to tumor suppressor genes, 28 were oncogenes, and 15 genes were classified as either fusion genes or both oncogene and tumor suppressor. For some genes, including TP53 (second column, Figure 3B ) and tumor suppressor CASP8 (third column, Figure   3B ), a strong linear relationship between mutability and recurrence frequency of observed mutations ( 2 > 0.5) was observed.
Relationship between mutability and observed frequency is different for tumor suppressor and oncogenes
The effects of mutations on protein function, with respect to their cancer transforming ability, can drastically differ in tumor suppressor genes (TSG) and oncogenes, therefore we performed our analysis separately for these two categories ( Figure 4 ). We used COSMIC gene classification separating genes into tumor suppressors and oncogenes. Genes which were annotated as both TSG and oncogenes were excluded from this analysis. Mutations in TSG can cause cancer through the inactivation of their products, whereas mutations on oncogenes may result in protein activation. In addition, we used COSMIC classification into genes with dominant or recessive mutations, but overall results were similar to the ones produced using classification into TSG and oncogenes ( Figure S6 ). The strongest correlation between codon mutability and mutation recurrence frequency was observed for TSG ( = 0.17, = 0.13, < 0.01) while oncogenes showed a weak Spearman correlation, and no significant Pearson correlation ( = 0.13, < 0.01, = 0, = 0.61) ( Figure S5 ).
A U-shaped trend was detected for missense and silent mutations in oncogenes: highly recurring mutations (observed in three and more samples) were characterized by a low average mutability ( Figure 4 ). In the latter case, selection may be a more important factor compared to background mutation rate explaining reoccurrence of these mutation. Functional conserved sites overall were found to be more frequently mutated in oncogenes [29] , although our analysis did not find a straightforward association between site mutability and its evolutionary conservation (data not shown).
Functionally neutral mutations have higher mutability
We complied a combined dataset of experimentally annotated missense mutations in cancer genes from several sources which were categorized as 'non-neutral' or 'neutral' based on their experimental effect on protein function, transforming effects, and other characteristics (see Methods). For our combined dataset, the mutability values of 'neutral' mutations were significantly higher (Mann-Whitney-Wilcoxon test, < 0.01) than for 'non-neutral' mutations ( Figure 5A ). Binning the mutations by their reoccurrence frequency also showed differences between 'neutral' and 'non-neutral', with the frequency of 'neutral' mutations depending on their mutability, so that mutations that were not observed in patients had the lowest mutability (µ = 2.54 x 10 -6 ), while those 'neutral' mutations that were observed in 3 or more samples had background mutability more than double (µ = 6.22 x 10 -6 ). The differences between non-neutral mutations which were not observed in patients (µ = 1.59 x 10 -6 ) and highly recurring mutations was considerably less pronounced (µ = 2.22 x 10 -6 ). These effects persisted when examining the mutations binned by frequency in the MSK-IMPACT cohort ( Figure S6 ).
Accounting for context-dependent mutability in ranking of mutations
In the previous sections we explored the contribution of background mutational processes in understanding the observed mutational patterns in cancer, with the ultimate goal to facilitate the detection of cancer driver mutations or provide a reasonable ranking in terms of their potential carcinogenic effects. Therefore, we tested how well our method could differentiate between experimentally annotated neutral, or putatively passenger mutations, and non-neutral driver mutations. For this purpose, we compiled a dataset from several experimental studies which included 5,276 annotated mutations in 58 different genes: 4,137 passenger mutations and 1,139 driver mutations (Table S3 ). We developed two measures which utilize background mutability. The first measure, log-ratio (LR, equation 4), was calculated as a logarithm of the ratio of the number of observed and expected mutations. The second measure (B-score, equation 5) was calculated from the binomial distribution as a probability to find a given mutation in a certain number of tumor samples or higher given the background context-dependent mutation rate. We compared the performance of these two scores to five other widely used computational methods, CHASM [30] , VEST [31] , REVEL [32] , CanDrAplus [33] and FatHMM [34] . Table 1 and Figure S9 show the performance of the various computational predictors at classifying the combined dataset. The best classifier on this dataset is REVEL, an ensemble method which uses the scores of 13 different tools. Intriguingly, despite being based only on mutational frequency, background mutability, and cohort size, and having no training involved, B-Score performs comparably well, with a Matthews correlation coefficient (MCC) of 0.53, just below that of REVEL's at 0.54 (Table 1 ). B-Score ties with FatHMM on the MCC, with FatHMM having higher AUC-ROC than B-Score (0.85 to 0.79), while having a lower sensitivity at 10% FPR (0.40 to 0.54). Observed frequency of the mutation recurrence in the COSMIC v85 cohort alone outperformed two of the trained computational predictors, CHASM and VEST. By integrating cohort size, B-Score is able to provide a correction to observed frequency using codon mutability and yields a much better performance than frequency alone, mutability, or a ratio of the two (LR). Mutability alone performed better than random with an MCC of 0.17 emphasizing the fundamental quality of non-neutral mutations in cancer: mutability of driver mutations is lower than the mutability of passengers ( Figure 5 ). Because B-Score relies on frequency of recurrence, we also explored performance on mutations that were not observed or observed only once in the COSMIC v85 cohort (Table S5 ). When mutation frequency is held constant, B-Score and mutability give the same rank order. For mutations which are not observed in the COSMIC cohort Our approach also allows to break ties for mutations observed in the same number of patients.
For example in the TP53 gene, mutations p.Arg181Cys, p.Arg282Gln, and p.Arg282Pro have been observed in two patients in a pan-cancer cohort on the MutaGene server. However, p.Arg181Cys (mutability of 1.00 x 10 -5 ) is considered a passenger mutation, p.Arg282Gln (mutability of 8.11 x 10 -6 ) -as a potential driver, and p.Arg282Pro (mutability of 4.90 x 10 -7 ) -as a driver mutation. Indeed, p.Arg282Pro is annotated as driver mutation in the experimental dataset, and despite the low recurrence frequency, it is correctly classified as a driver by our method. While there are methods based on hotspot identification, our ranking of mutations based on our method cannot be directly compared to the list of hotspots proposed previously [21] . Hotspots are defined for sites, whereas our method assesses specific mutations, and different mutations from the same hotspot can be drivers or passengers. For instance, TP53 Tyr236 site is annotated as a hotspot in [21, 35] , however p.Tyr236Phe mutation is experimentally characterized as neutral in the IARC database.
Variability of mutation rates across genes
Even though our probabilistic model indirectly incorporates different factors, we checked explicitly if large-scale factors, allowing mutations of the same type to have different mutational probabilities in different genes, affected retrieval performance on our combined test set. Several methods have been developed to estimate gene weights (see Methods), which use the overall number of mutations, number of silent mutations affecting a gene, or other factors. We implemented and tested these approaches (see Methods) and in addition estimated the gene weights based on the number of SNPs in the vicinity of a gene. We used gene weights to adjust mutability values and explored whether any of the gene weight models were helpful in distinguishing between experimentally neutral and driver non-neutral mutations. We examined the effects of several large-scale confounding factors such as gene expression levels, replication timing, and chromatin accessibility (provided in the gene covariates files for MutSigCV [36] ) on gene weights. We found that "no-outlier"-based weight and "silent mutation"-based weight significantly correlated with the gene expression levels ( = 0.66, = 0.004 and = 0.65, = 0.004 , respectively). Overall, using gene weight as an adjustment for varying background mutational rates across genes did not improve classification performance. Only a SNP-based weight affected the AUC-ROC, but the gain was very minimal, and no gene weight affected MCC (Table S6 ).
Ranking of cancer point mutations in MutaGene
MutaGene webserver provides a collection of cancer-specific context-dependent mutational profiles and allows to calculate nucleotide and codon mutability and B-Score for missense, nonsense and silent mutations for any given protein coding DNA sequence and background mutagenesis model using the "Analyze gene" option. Following the analysis presented in this study, we added options to provide a ranking of mutations observed in cancer samples based on the B-Score or the multiple-testing adjusted q-values. Using the combined dataset as a performance benchmark (Table 1, Figure S9 ), we calibrated two thresholds: the first corresponds to the maximum MCC, and the second corresponds to 10% false positive rate. Mutations with B-Score below the first threshold are predicted to be "cancer drivers", whereas mutations with scores in between two thresholds are predicted to be "potential drivers". All mutations with scores above the second threshold are predicted as "passengers". Importantly, calculations are not limited to pan-caner and can be performed using a mutational profile for any particular cancer type, the latter would result in a cancer-specific ranking of mutations and could be useful for identification of driver mutations in a particular type of cancer. An example of prediction of driver mutations status for EGFR is shown in Figure 6 .
Discussion
To understand what processes drive point mutation accumulation in cancer, we used DNA context-dependent probabilistic models to estimate the baseline mutability for nucleotide mutation or codon substitution in specific genomic sites. Passenger mutations, constituting the majority of all observed mutations, may have largely neutral functional impacts and are unlikely to be under selection pressure. For passenger mutations one would expect that mutations with lower DNA mutability would have lower observed mutational frequency and vice versa. In accordance with this expectation, we detected a significant positive correlation between background mutability, which is an estimate of per site mutation rate, and observed frequencies of mutations in cancer patients. In a recent study the fraction of sites harboring SNPs in the human genome was found indeed to correlate very well with the mutability although the later was estimated differently from our study [37] . We also found that cancer mutations not so far observed in cancer patients had much lower expected background nucleotide and codon mutability compared to the observed mutations For some genes, the observed frequency of occurrence of mutations can be predicted purely from their mutability. Outliers of this trend are important for inferring mutations under selection. For instance, if a mutation with low expected mutation rate is observed in multiple patients, it is suggestive of it being potentially important in carcinogenesis. In this respect, reoccurring synonymous mutations with low mutability may represent interesting cases for further investigation of potential synonymous drivers.
Mutability of synonymous mutations was found to be the highest among other types of mutations; and observed mutational frequency of these mutations scaled very well with their mutability. Overall, our method predicted 102 synonymous driver mutations in 64 out of 520 cancer-associated genes. Indeed, it has been previously shown that some synonymous mutations might be under selection, and can affect the speed and accuracy of transcription and translation, protein folding rate, and splicing [38] . Since observed mutational frequency of synonymous mutations scales with their mutability (Figures 1,4) , it is important to correct for mutability while ranking these mutations with respect to their driver status. Some recurrent highly mutable synonymous mutations might not represent relevant candidates of drivers, whereas some rare mutations with relatively low mutability are predicted to be drivers by our method (e.g. KDR gene p.Leu355=, NTRK1 gene p.Asn270=).
We developed and tested a probabilistic model to adjust the number of reoccurrences of a mutation by its expected background mutability in order to find those sites and mutations which may be under selection in cancer. We find that while including background mutability improves performance over reoccurrence alone in distinguishing between driver and passenger mutations, the choice of how to account for mutability is also important. Our B-Score integrates information about observed rate and total cohort size, something not captured by an odds ratio alone. The advantages of this model are that: (i) it is intuitive (ii) does not rely on many parameters and (iii)
does not involve explicit training on driver and passenger mutation sets. One of the disadvantages of this model is that it requires the knowledge of a total number of patients tested.
We found that B-Score exhibited a considerably improved performance of driver mutation prediction compared to the conventional way of using mutational frequency of occurrence. It performed comparably or better to state-of-the-art methods even for rare mutations observed in cancer patients; many of the methods we used for comparison were trained on existing datasets of mutations and relied upon multiple features. However, the performance of B-Score was detrimental for mutations not observed in cancer patients. Moreover, for highly heterogeneous cancer types, the background mutational processes may differ between cohorts of cancer patients, thus an appropriate cancer-specific model for background mutability should be applied. Taken together, our model provides means to explore mutation rates and enables an understanding of the differential roles that background mutation rate and selection play in shaping the observed cancer spectrum.
For our analysis of methods' performance using a dataset with experimentally determined effects of mutations combined from different studies, we had to apply a pan-cancer mutability model.
While mutational processes vary widely among cancer types, and different drivers mutations have been shown to be preferentially associate with specific mutational signatures [39, 40] there remains a lack of cancer-specific driver/passenger datasets. It may be insightful for researchers to apply cancer-specific B-Score ranking of mutations using the models available on the MutaGene website.
Some efforts have been focused so far on developing a comprehensive set of cancer driver mutations verified at the levels of functional assays or animal models [26, 41, 42] . However, existing sets often contain predictions and very few neutral passenger mutations. The vast majority of computational prediction methods rely on machine learning algorithms trained on mutations from a few genes and/or on recurrent mutations as estimates of driver events or use germline SNPs or silent mutations as the presumed "neutral" set. In many cases, the performance is evaluated on similarly generated synthetic benchmarks. As a result, methods can be trained on incorrectly labeled data, predicting cancer driver mutations worse than their recurrence frequency (Table 1) or background mutability alone (Table S5 ). In this study, we restricted our dataset to only missense mutations that have been experimentally assessed, with overall 4,137 passenger and 1,139 driver mutations from 58 genes. Intriguingly, we found that experimentally annotated driver mutations have a lower background mutability than neutral mutations, suggesting possible action of context-dependent codon bias towards less mutable codons at critical sites for these genes, although more studies would have to be conducted to further investigate this observation.
Methods
Defining drivers and passengers -datasets of experimental functional assays
Missense mutations for TP53 gene with experimentally determined functional transactivation activities were obtained from IARC P53 database where they were classified as functional, partially-functional, and non-functional [43] .
The second dataset, referred hereinafter to as "Martelotto et al.", contains experimental evidence collected from literature [44] . The experimental evidence of impact of mutations included changes in enzymatic activity, response to ligand binding, impacts on downstream pathways, an ability to transform human or murine cells, tumor induction in vivo, or changes in the rates of progression-free or overall survival in pre-clinical models. In "Martelotto et al."
dataset mutations were considered "damaging" if there was literature evidence to support their impact on at least one of the above-mentioned categories. Mutations with no significant impacts on the wild-type protein function were classified as "neutral". Mutations with no reliable functional evidence were regarded as "uncertain" and were not used in this study.
The third dataset included experimentally verified BRCA1 mutations and was originally collected by using deep mutational scanning to measure the effects of missense mutations on the ability of BRCA1 to participate in homology-directed repair. Missense mutations were categorized as either "neutral" or "damaging" [45, 46] . Noteworthy, BRCA1 set contained inherited germline as well as somatic mutations.
The fourth dataset explored over 81,000 tumors to identify drivers of hypermutation in DNA polymerase epsilon and delta genes (POLE/POLD1). "Drivers of hypermutation" were variants which occurred in a minimum of two hypermutant tumors, which were never found in lowly mutated tumors, and did not co-occur with an existing known driver mutation in the same tumor.
Other variants in these genes were considered "passengers" with respect to hypermutation [25] .
The fifth dataset consisted of missense mutations annotated based on their effects on cellviability in Ba/FC and MCF10A models [47] . "Activating mutations" were mutations where the cell viability was higher than the wild-type gene, and "neutral mutations" were those mutations where cell-viability was similar to the wild-type. Ng Finally, we assembled a combined dataset that included mutations from these five datasets described above. We removed redundant and conflicting entries when mutations annotated as non-functional or neutral in one dataset were also annotated as damaging or benign in another.
All mutations were categorized as "non-neutral" (affecting function, binding or transforming) and "neutral" (other mutations). We treated "functional" and "partially -functional" mutations in IARC TP53 dataset as "neutral", and "non-functional" as "non-neutral". We used missense mutations in order to compare with cancer FatHMM scores. Overall, the combined dataset contains 5,276 mutations (4,137neutral and 1,139 non-neutral) from 58 genes (Table S3 , S7).
Datasets of cancer mutations
The Catalogue of Somatic Mutations in Cancer (COSMIC) database stores data on somatic cancer mutations and integrates the experimental data from the full-genome (WGS) and whole-exome (WES) sequencing studies [48] . Cancer census genes (520 genes) were defined according to COSMIC release v84. For analyses comparing oncogenes and TSG, genes classified as only fusion genes or those with both oncogenic and TSG activities were not used. This resulted in 205 oncogenes and 167 TSG (Table S2) Because of this relatively stringent criteria for inclusion, it is likely that some small number of non-duplicate samples were discarded in this process.
MSK-IMPACT cohort was obtained from cBioPortal [49] . We ensured that no mutations were counted multiple times for each patient; if there were multiple tumor samples per patient, primary and metastatic, the primary tumor was kept, and the metastatic discarded. Only those tumors which were sequenced against a "matched" normal sample were kept to ensure validity of somatic mutations.
In the 520 genes we explored, we found that 250 genes contained at least one mutation annotated as a driver by our method. We investigated if these genes were expressed in cancer cell lines from multiple tissue types using RNAseq data from the Cancer Cell Line Encyclopedia [50] . Using RNAseq data of 1,076 unique cancer cell lines from 26 different tissue types and a cut off for expression at 0.5 RPKM (Reads Per Kilobase of transcript, per Million mapped reads), we found that genes with driver mutations were expressed in 5,646 out of 6,506 gene-tissue comparisons.
Calculation of context-dependent DNA background mutability
Context-dependent mutational profiles were constructed from the pools of mutations from different cancer samples by counting mutations observed in a specific trinucleotide context. the assumption that vast majority of cancer context-dependent mutations have neutral effects, while only a negligible number of these mutations in specific sites are under selection. To assure this, we removed recurrent mutations (observed twice or more times in the same site) as these mutations might be under selection in cancer. In the current study we used pan-cancer and cancer-specific mutational profiles for breast, lung adenocarcinoma, and skin adenocarcinoma cancer derived from MutaGene [51] .
We applied mutational profiles to build DNA context-dependent probabilistic models that described baseline DNA mutagenesis per nucleotide or per codon. Mutability was defined as a probability to obtain a context-dependent nucleotide mutation purely from the baseline mutagenic processes operating in a given group of samples used to derive the mutational profile.
Mutability is proportional to the expected mutation rate of a certain type of mutation (96 altogether) regardless of the genomic site it occurs. It was calculated using the total number of mutations of type x ≫ y in a certain local context, which can be obtained from the contextdependent mutational profile, . Given the number of cancer samples used to construct mutational profile, N, and the number of different trinucleotides of type t in a diploid human exome, (calculated from the reference genome), the nucleotide mutation mutability is calculated as:
In protein-coding sequences it is practical to calculate mutation probability for a codon in its local pentanucleotide context, given trinucleotide contexts of each nucleotide in the codon. For a given transcript of a protein, at exon boundaries the local context of the nucleotides was taken from the genomic context. The COSMIC consensus transcript was chosen for the transcript for each protein. Changes in codons can lead to amino acid substitutions, synonymous and nonsense mutations. Therefore, we calculate codon mutability as the probability to observe a specific type of codon change which can be realized by single nucleotide mutations at each codon position i as:
Where k denotes a number of mutually exclusive mutations at codon position i. For example, for Figure   S4 ). In this case the probability of Phe→ Leu substitution in the context can be calculated
where trinucleotide probabilities were taken from the mutational profile. Amino acid substitutions corresponding to each missense mutation are calculated by translating the mutated and wild type codons using a standard codon table. Codon mutability strongly depends on the neighboring codons as illustrated in Figure S4 .
Gene-weight adjusted mutability
Gene weights estimate a relative probability of a gene compared to other genes to be mutated in cancer through somatic mutagenesis. There are multiple ways the gene weights can be calculated.
SNP-based weight was calculated using the number of SNPs in the vicinity of the gene of interest.
We used the "EnsDb.Hsapiens.v86" database to find genomic coordinates of a gene, including introns, and extended the range in both 3' and 5' directions according to the window size (Table   S7 ). We then counted the number of common SNPs from dbSNP database [52] within the genomic region. Gene weight was calculated as: = , where is the number of SNPs and is the length of the genomic region in base pairs. We tested several window sizes for defining the genomic regions around the gene of interest (Table S6) .
Mutation-based weight was calculated using the number of nucleotide sites with reoccurring mutations counted only once to avoid the bias that may be present due to selection on individual sites:
Here is the number of mutated sites and is the number of base pairs in the gene transcript.
Silent mutation-based weight was introduced previously and was shown to be superior in assessment of significant non-synonymous mutations across genes [53] . This weight can be calculated by taking into account only silent somatic mutations: = .
Here is the total number of somatic silent mutations within the gene, is the number of tumor samples and is the number of codons in the gene transcript.
No-outlier-based weight introduced previously [21] takes into account the number of all codon mutations within a gene, , excluding mutations in outlier codon sites bearing more than the 99 th percentile of mutations of the gene: = , normalized by gene length in amino acids and the total number of samples .
Using gene weights, an adjusted probability per codon can be then expressed as:
Similarly, per nucleotide probability can be calculated adjusted by gene weight.
Identification of significant mutations
We introduced two measures which take into account the background DNA mutability. The first measure (LR) is calculated as a ratio of the numbers of observed and expected mutations in a given nucleotide site or in a given codon:
where the expected number of mutations, = or = where N is the number of tumor samples and or are calculated using equations (1) or (2) and the observed number of mutations in a given site is taken from COSMIC v85 with a pseudo count correction ( + 1) to account for mutations that have not been observed due to a limited tumor sample collection.
The second measure uses the binomial model to calculate the probability of observing a certain type of mutation in a given site more frequently than k:
where = ′ or = ′ and is the number of observed mutations of a given type at a particular nucleotide or codon. Depending on the dataset chosen or a particular cohort of patients (for instance, corresponding to one cancer type), the total number of samples and the numbers of observed mutations will change. While ranking mutations in a given gene, can further be adjusted for multiple-testing with Benjamini-Hochberg correction as implemented on the MutaGene website.
Computational Predictions
CanDrAplus 34 program was downloaded and ran using default specifications with the "Cancer-in-General" annotation data file. REVEL 33 predictions were obtained from dbNSFP database [54] .
CHASM 31 and VEST 32 were obtained using CRAVAT [55] . Several versions of CHASM 31 are available, and we used the version which performed the best on the combined dataset.
FatHMM 35 cancer-associated scores were obtained from their webserver.
Statistical and ROC analyses
Differences between various groups were tested with the Kruskal-Wallis, Dunn test, and Mann-Whitney-Wilcoxon tests implemented in R software. Dunn's test is a non-parametric pairwise multiple comparisons procedure based on rank sums; it is used to infer difference between means in multiple groups and was used because it is relatively conservative post-hoc test for Kruskal-Wallis. Associations between mutability and observed frequency (the number of individuals with a mutation in whole-exome/genome studies from COSMIC), was tested using
Pearson as well as Spearman correlation tests since the variables were not normally distributed.
Where R reports the calculated p-value below 2.2 x 10 -16 , the value has been shown as the alpha level, < 0.01.
To quantify the performance of scores, we performed Receiver Operating Characteristics (ROC) and precision-recall analyses. Sensitivity or true positive rate was defined as TPR=TP/(TP + FN) and specificity was defined as SPC=TN/(FP+TN). Additionally, in order to account for imbalances in the labeled dataset, the quality of the predictions was described by Matthews correlation coefficient:
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